Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25434721 | 0.86 | NR1H2 (0.39) | OPRL1NR1H2NR1H3RXRARORC | |
| SCHEMBL26059137 | 0.85 | OPRL1 (0.41) | OPRL1RORC | |
| SCHEMBL26062015 | 0.85 | OPRL1 (0.41) | OPRL1RORC | |
| SCHEMBL31387359 | 0.85 | OPRL1 (0.41) | OPRL1RORC | |
| SCHEMBL30623219 | 0.85 | OPRL1 (0.41) | OPRL1RORC | |
| SCHEMBL30534303 | 0.80 | OPRL1 (0.39) | OPRL1RORC | |
| SCHEMBL1807425 | 0.79 | OPRL1 (0.47) | OPRL1NR1H2RORC | |
| SCHEMBL18579655 | 0.76 | OPRL1 (0.45) | OPRL1RORC | |
| SCHEMBL29116171 | 0.75 | NR1H2 (0.47) | NR1H2NR1H3RXRARORC | |
| SCHEMBL29116170 | 0.75 | NR1H2 (0.47) | NR1H2NR1H3RXRARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136612-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2025-05-01 | — | — | US | disclosed |
| EP-4476228-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119013281-A | 4',5' -Dihydrospiro [ piperidine-4, 7' -thieno [2,3-C ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136612-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PDXK, PNLIP | OPRL1 98/4885NR1H2 464/4885NR1H3 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.